MOLECULIN BIOTECH, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • September 15th, 2017 • Moleculin Biotech, Inc. • Pharmaceutical preparations • New York
Moleculin Biotech, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with Roth Capital Partners, LLC (“ ROTH”), and National Securities Corporation (“National” and ROTH, individually an “Agent” and collectively, the “Agents”) as follows:
